iBio develops vaccine candidate for H7N9 influenza virus
The laboratory achieved the validation milestone for the candidate in 21 days from initial antigen sequence information to the final purification of recombinant protein stage. The H7N9 virus has infected 131 people in China, killing 36 of the infected individuals.
Conventional approaches to vaccine development and production are slow and require healthcare systems to provide only patient isolation and supportive care. The iBioLaunch platform removes the need to culture cells under sterile conditions, eliminates uncertainty about yield consistency for large production volumes and could deliver vaccine doses for emergency use against bioterrorism and pandemic threats in weeks rather than months.
The platform is subject to regulatory approval.
The iBioLaunch platform has been used to produce vaccine-quality antigens for H7N7, H5N1, H3N1, H1N1 and multiple strains of influenza B.
iBio develops and offers the applications of its iBioLaunch and iBioModulator platforms for the development of proprietary and biosimilar products. The iBioLaunch platform uses transient gene expression in unmodified green plants to develop biologics. The iBioModulator platform is meant to significantly improve vaccine products with greater duration of effect and higher potency.